Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14747MR)

This product GTTS-WQ14747MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF8 gene. The antibody can be applied in Anaplastic large cell lymphoma (ALCL), Hodgkin lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001243.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 943
UniProt ID P28908
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14747MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10529MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3015014
GTTS-WQ15244MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA TAK-079
GTTS-WQ12790MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ13061MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ4503MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ455MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 3G3
GTTS-WQ13010MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ667MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 8H9
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW